NCT02660372已完成3 期
A Multi-center, Randomized, Observer-blind, Parallel Group, 8-weeks Non-inferiority Clinical Trial to Compare the Efficacy and Safety of Two Brands of Simeticone for Symptomatic Treatment of Functional Dyspepsia in Adults
Johnson & Johnson Consumer and Personal Products Worldwide1 个研究点 分布在 1 个国家目标入组 210 人开始时间: 2016年2月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 210
- 试验地点
- 1
- 主要终点
- Aggregate symptom score calculated from subjects assessment of 10 individual upper gastrointestinal symptoms 8 weeks after start of treatments
研究概览
简要总结
The aim of this study is to show non-inferiority of two brands of simeticone in adult patients suffering from functional dyspepsia.
详细描述
This is a multi-center, randomized, observer-blind, parallel-group, 8-weeks, non-inferiority clinical trial to compare the efficacy and safety of two brands of Simeticone for symptomatic treatment of functional dyspepsia in adults.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects of the age of 18 years or older with a suspected diagnosis of functional dyspepsia according to Rome III criteria (see Appendix A) e.g. subjects suffering from bothersome postprandial fullness or early satiation or epigastric pain or epigastric burning AND no evidence of structural disease (including upper GI endoscopy) that is likely to explain the symptoms. Criteria fulfilled for the last 3 months. Symptom onset at least 6 months prior to diagnosis.
- •Have a Body Mass Index (BMI) between 18.5-
- •Absence of significant structural/organic abnormalities on abdominal ultrasound and upper gastrointestinal endoscopy performed within the last 3 months prior to baseline to exclude a structural cause for the symptoms.
- •Negative Helicobacter Pylori urea breath test.
- •Presence of at least three out of the assessed ten symptoms judged to be at least of moderate or severe intensity, assessed after withdrawal of any medication potentially affecting the gastrointestinal tract and at least 7 days wash-out period.
- •Females of childbearing potential must have a negative urine pregnancy test at the baseline visit.
- •Male or non-pregnant, non-lactating female agree to the contraceptive requirements (including female partner's use of a highly effective form of birth control for at least 3 months before the study, during the study and for 3 months after the last dose of study drug) as outlined in Section 10.7.
- •Able to read and understand the local language;
- •Provide a signed and dated informed consent form prior to any study-related procedures;
- •Willing and able to comply with all study procedures and attend the scheduled visits for the duration of the study.
排除标准
- •Subjects meeting the diagnostic Rome III criteria for Irritable Bowel Disease (IBS) (see Appendix A).
- •a) severe gastroesophageal reflux symptoms (typical symptoms - heartburn, regurgitation, dysphagia, odynophagia, and/or signs of reflux at upper GI endoscopy) at Screening visit.
- •b) predominant gastroesophageal reflux symptoms defined as a Subject's Symptom Severity Score of 2 or more for heartburn and regurgitation at Baseline visit after the 7-days wash-out period (see questionnaire in Appendix B).
- •Significant medical condition which may interfere with a subject's participation in the study, e.g. diabetes mellitus, thyroid dysfunction, renal insufficiency, congestive heart failure, electrolyte disturbances or autoimmune diseases requiring immunosuppressive treatment.
- •Known hepatic, biliary or pancreatic disease.
- •Known lactose or gluten intolerance or celiac disease.
- •Known HIV positive or AIDS.
- •Suspected alcohol or substance abuse (e.g., amphetamines, benzodiazepines, cocaine, marijuana, opiates).
- •Unwillingness or inability to withdraw and abstain from medication which is likely to affect gastrointestinal function or symptoms during the 7-days wash-out period and throughout the study period, including the following drugs:
- •gastrointestinal medications including antispasmodics, prokinetics, proton pump inhibitors, H2 blockers, antacids, alginate, bismuth preparations, sucralfate, misoprostol, charcoal, diosmectite, enzymes (e.g. Kreon®, Mezim®).
- •other medications that could interfere with gastrointestinal function e.g. antibiotics (except for local application), theophylline, NSAIDs (except for low-dose aspirin for prevention of heart disease), opioid analgesics, codeine, ulcerogenic substances (e.g. oral glucocorticoids), anxiolytics, neuroleptics, antidepressants, and/or others in the judgment of the investigator.
- •Females who are pregnant or breastfeeding.
- •Males with a pregnant partner or a partner who is currently trying to become pregnant.
- •Known sensitivity to the investigational products.
- •Subjects who were previously screened and ineligible or were randomized to receive investigational product.
- •Currently participating in another clinical trial or has done so in the past 30 days.
- •Subjects who are related to those persons involved directly or indirectly with the conduct of this study (i.e., principal investigator, subinvestigators, study coordinators, other site personnel, employees of Johnson & Johnson LLC or McNeil AB subsidiaries, contractors of Johnson & Johnson LLC or McNeil AB, and the families of each).
- •Other severe, acute or chronic, medical or psychiatric condition(s) or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
研究组 & 干预措施
Imonogas
Experimental
Imonogas 120 mg, 1 capsule three times daily for 8 weeks
干预措施: Imonogas (Drug)
Espumisan
Active Comparator
Espumisan 40 mg, 2 capsules four times daily for 8 weeks
干预措施: Espumisan (Drug)
结局指标
主要结局
Aggregate symptom score calculated from subjects assessment of 10 individual upper gastrointestinal symptoms 8 weeks after start of treatments
时间窗: 8 weeks
Specific questionnaire with a 4 point scale
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
终止
3 期
Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Cutaneous Rash TreatmentCutaneous HypersensitivityNCT01529242EMS17
已完成
3 期
Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Persistent Allergic Rhinitis TreatmentAllergic RhinitisNCT01529229EMS210
已完成
3 期
Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal OsteoporosisPostmenopausal Women With OsteoporosisNCT03974100Sandoz527
Unknown
3 期
Comparison of Desloratadine Associated With Prednisolone (Tablet)Versus Dexchlorpheniramine Associated With Betamethasone (Tablet) for Adult Persistent Allergic Rhinitis TreatmentAllergic RhinitisNCT01720485EMS234
已完成
3 期
Study of Recovery of Strength After Surgery Comparing Two Different Medications for Reversal of Muscle RelaxantSurgeryNCT03116997Memorial Sloan Kettering Cancer Center201